BioMedNewsBreaks — MetAlert Inc. (MLRT) ‘Groundbreaking’ Tech for Senior Health Care Market Spotlighted in Recent Article

MetAlert (OTC: MLRT), a pioneer in the field of wearable GPS human and asset tracking and remote patient monitoring, is featured in a recent Market Herald article for its proprietary technologies, including RoomMate(TM). The article, which is titled “One Company Is Set to Pioneer Technologies for the Senior Health Care Market,” reports on RoomMate, MetAlert’s groundbreaking 3D fall detection and monitoring device. The 3D infrared fall-detection, automated monitoring system provides “anonymized” supervision and monitoring service using infrared 3D tech. The article noted that more than 5,500 devices are in operation in Norway, Sweden, Denmark and Iceland, and the company is beginning marketing and distribution efforts in the United States, Canada and the United Kingdom. “MetAlert has ambitious plans to penetrate these high CAGR-projected markets, and it is well positioned to become a dominant player in the growing senior and home care market,” the article stated. “MetAlert presents a compelling opportunity for stock investors to invest in a company with a strong track record of innovation and a bright future ahead. A partnership with the Sensio Group further strengthens MetAlert’s position in the market and reinforces its commitment to providing innovative solutions for seniors and those who care for them. With RoomMate, MetAlert is helping seniors feel safe and secure while still getting independence.”

To view the full article, visit https://ibn.fm/LjM7g

About MetAlert Inc.

MetAlert, a pioneer in smart, mobile, and wearable tracking and recovery location-based solutions, is supported through a proprietary IoT enterprise monitoring platform and intellectual property portfolio. The company offers a global end-to-end solution of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications. Utilizing the latest in miniaturized, low-power consumption GPS, cellular, RF, NFC and BLE technology, MetAlert products enable subscribers to track in real time the whereabouts of people or high-value assets. Known for its game-changing and award-winning patented GPS SmartSole — think Dr. Scholl’s meets LoJack, the world’s first invisible, wearable, technology-tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism or traumatic brain injury. MetAlert’s business model is built around technology innovation and holds dozens of patents, with many issued patents in the area of GPS tracking. The company has international distributors servicing customers across the globe with subscribers in more than 40 countries; MetAlert is also a U.S. military government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. For more information about this company, please visit www.MetAlert.com

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Granted 180-Day Nasdaq Extension to Regain Minimum Bid Price Compliance

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology…

15 hours ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Receives FDA Meeting Feedback Advancing AVERSA(TM) Fentanyl Toward 505(b)(2) NDA Submission 

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, today announced it has received…

1 day ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Innovations in Oncology

Oncotelic Therapeutics (OTCQB: OTLC) today announced its inclusion in an editorial published by NetworkNewsWire (“NNW”),…

1 day ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its RADR(R) AI platform to transform…

2 days ago

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Partners with HeartNexus to Deliver 24/7 Remote Cardiology Services and Real-Time ECG Interpretation

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights,…

2 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Founder Gareth Sheridan Returns as CEO to Lead Final Development Phase of AVERSA Fentanyl 

Nutriband (NASDAQ: NTRB) today announced that company founder Gareth Sheridan has resumed his role as…

2 days ago